In addition, the identification of the FDA-approved druggable target (HDAC3) and the four immune checkpoint molecules in BM suggest that targeted therapies should be tailored for specific tumor lineages in order to effectively manage brain metastasis. This evidence concerns the gene HDAC3 and neoplasm.